Molecular Properties
| Parameter | Value |
|---|---|
| Chemical Name | Hexarelin / Examorelin |
| Amino Acid Sequence | His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular Formula | C₄₇H₅₈N₁₂O₆ |
| Molecular Weight | 887.04 g/mol |
| CAS Number | 140703-51-1 |
| Sequence Length | 6 amino acids (synthetic hexapeptide with D-amino acids and methylation) |
| Receptor Target | Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor; CD36 |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.0-7.0 |
| pH (1% solution) | 5.0 - 7.0 |
| Hygroscopicity | Low to moderate; standard desiccated storage |
| Solution Stability | Stable at 4°C for 10-14 days; enhanced stability from D-amino acids and methylation |
Analytical Specifications
| Test | Specification |
|---|---|
| HPLC Purity | ≥98.0% |
| Mass Spectrometry | Confirmed [M+H]⁺ = 887.04 ± 0.5 Da |
| Peptide Content | ≥95% (by amino acid analysis) |
| Endotoxin Level | <1.0 EU/mg |
| Acetate Content | ≤5% |
| TFA Content | ≤0.1% |
| Water Content | ≤6% (Karl Fischer) |
Storage Parameters
| Condition | Specification |
|---|---|
| Lyophilized Storage | -20°C, desiccated, protected from light |
| Lyophilized Shelf Life | 24-36 months when stored properly |
| Reconstituted Storage | 2-8°C for up to 14 days; -20°C for up to 3 months |
| Analytical Stock Preparation | Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds |
| Freeze-Thaw Cycles | Tolerates up to 5 cycles; superior stability vs unmodified peptides |
| Light Sensitivity | Moderate; store in amber vials recommended |
In Vitro & Preclinical Model Concentrations
| Experimental Model | Published Concentration / Regimen | Exposure Schedule | Administration Context |
|---|---|---|---|
| In Vitro Pituitary Cell Assays | 1-500 nM | Acute stimulation (30 min to 2 hours) | Culture media |
| Small Animal Models (Rodent) | 50-300 μg/kg | 1-2x daily | SC, IV, or oral in rodent models |
| GH Secretion Studies (Rodent) | 100-200 μg/kg | Single dose or repeated for 7-28 days | SC in rodent models |
| Cardioprotection Research (Rodent) | 80-160 μg/kg | Daily or BID for 1-4 weeks | SC or IV in rodent models |
Note: Concentrations and animal regimens summarized above are for research reference only. Hexarelin is intended strictly for laboratory research.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 1995 | Discovery and potency characterization | 2-methyl-D-Trp modification at position 2 increased GH-releasing potency 5-10x vs GHRP-6; demonstrated EC₅₀ of 0.05-0.5 nM (most potent synthetic GHRP); maintained stability and oral bioactivity |
| 2000 | Cardioprotective effects in ischemia models | Hexarelin (80 μg/kg BID) reduced myocardial infarct size by 40-50% in animal models; effects partly GHS-R1a-independent; identified CD36 receptor interaction mediating cardiac protection |
| 2006 | Multi-organ protective effects | Chronic hexarelin administration protected heart, kidney, liver from ischemia-reperfusion injury in animal models; anti-apoptotic effects via CD36 activation; reduced inflammatory cytokines 30-50%; GH-independent mechanisms identified |
| 2011 | Cortisol and prolactin co-secretion | Hexarelin stimulation increased cortisol 2-3x and prolactin 3-5x alongside GH release; greatest ACTH/cortisol stimulation among GHRPs; limits therapeutic application but valuable research tool |
Mechanism of Action
| Biological Pathway | Description |
|---|---|
| GHS-R1a Activation | Most potent GHS-R1a agonist (Kd ~0.1-1 nM); 5-10x more potent than GHRP-6 for GH release; stimulates pituitary somatotrophs and hypothalamic GHRH neurons |
| GH/ACTH/Prolactin Secretion | Strongest GH release among GHRPs; significant ACTH/cortisol co-stimulation (2-3x baseline); prolactin elevation (3-5x); peak GH at 15-30 minutes post-stimulus |
| CD36 Receptor Activation | Binds CD36 (fatty acid translocase) with moderate affinity; mediates cardioprotection, anti-inflammatory effects, and anti-apoptotic actions independent of GH |
| Cardioprotection | Direct cardiac effects via CD36; reduces oxidative stress; inhibits apoptosis; improves post-ischemic recovery; preserves contractile function in animal models |
| Half-Life | 30-70 minutes (IV/SC); 2-methyl modification increases stability; oral bioavailability 5-10% (unusual for peptides) |
Comparative Analysis: Hexarelin Potency
| Compound | GH Release EC₅₀ | Relative Potency | ACTH/Cortisol Effect |
|---|---|---|---|
| Hexarelin | 0.05-0.5 nM | 10x (reference) | Strong (2-3x) |
| GHRP-2 | 0.1-1 nM | 5-8x | Moderate (1.5-2x) |
| GHRP-6 | 0.2-2 nM | 5x | Moderate (1.5-2x) |
| Ipamorelin | 1-10 nM | 1x | Minimal (no increase) |
| GHRH (Sermorelin) | 0.5-2 nM | 1-2x | None |
Quality Control Parameters
| Test Method | Acceptance Criteria |
|---|---|
| Appearance (visual) | White to off-white powder; no discoloration |
| 2-Methyl-D-Trp Verification | Position 2 modification confirmed by MS/MS; methylation >98% |
| Chiral Purity | D-amino acids at positions 2 and 5 confirmed; >98% stereochemical purity |
| RP-HPLC (purity) | Main peak ≥98.0%; no single impurity >0.5% |
| ESI-MS (identity) | [M+H]⁺ = 887.04 ± 0.5 Da confirmed |
| Biological Activity | ≥90% potency vs reference in GH release assay |
Structure-Activity Relationship
| Position | Amino Acid | Structural Role |
|---|---|---|
| 1 | L-His | N-terminal; imidazole ring; similar to GHRP-6 |
| 2 | D-2-Methyl-Trp | KEY MODIFICATION: 2-methyl group increases potency 5-10x; D-configuration essential; enhanced receptor binding |
| 3 | L-Ala | Conformational spacer |
| 4 | L-Trp | Essential for GHS-R1a activation; indole ring critical |
| 5 | D-Phe | Receptor selectivity; D-configuration prevents degradation |
| 6 | L-Lys-NH₂ | C-terminal; positive charge; amidation required |
Reported Biological Effects
| Effect Category | Observed Changes | Timeframe |
|---|---|---|
| GH Secretion | Peak GH increase 10-30x baseline (highest in GHRP class); occurs 15-30 min post-stimulus | Acute (15-60 minutes) |
| ACTH/Cortisol | Increased ACTH 2-3x, cortisol 2-3x (strongest among GHRPs); limits chronic application | Acute (30-90 minutes) |
| Prolactin | Elevated 3-5x baseline; dose-dependent response | Acute (30-120 minutes) |
| Cardioprotection | Reduced infarct size 40-50% in rodent models; improved ejection fraction; anti-apoptotic effects | Hours to days |
| Appetite | Moderate increase (+20-40%); less than GHRP-6 but present | 1-3 hours |
Regulatory & Compounding Status
Hexarelin (Examorelin) is an unapproved investigational research peptide. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.
External References
- Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-9. https://academic.oup.com/jcem/article/86/4/1464/2849229
- Muccioli G, et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):27-31. https://pubmed.ncbi.nlm.nih.gov/10790589/
- National Center for Biotechnology Information. PubChem Compound Summary for Hexarelin. https://pubchem.ncbi.nlm.nih.gov/compound/Hexarelin
